Free-pricing holiday for new drugs in Germany a potential target
This article was originally published in SRA
Executive Summary
Drug companies in Germany could see lower prices for their new products take effect sooner and potential delays to launch if German policymakers do away with the 12-month grace period of free pricing for new drugs before the outcome of early benefit assessments and pricing talks kick in. The warning comes from Wolfgang Kaesbach, a former head of the pharmaceutical department of the GKV, the national association of statutory health insurers.